Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.02EUR
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
€5.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
288,414
52-wk High
€15.83
52-wk Low
€4.33

Latest Key Developments (Source: Significant Developments)

Innate Pharma provides an update on lirilumab
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.‍‍ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018​.  Full Article

Innate Pharma Q3 revenue up at 12.4 million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.  Full Article

Innate Pharma H1 operating loss widens to 18.2 million euros
Monday, 18 Sep 2017 

Sept 18 (Reuters) - INNATE PHARMA SA ::‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS(1) FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​.‍A NET LOSS FOR FIRST HALF OF 2017 AMOUNTING TO EUR 23.4M (EUR 3.2M FOR FIRST HALF OF 2016).​.H1 REVENUE EUR 21.3 MILLION VERSUS EUR 20.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 18.2 MILLION VERSUS LOSS OF EUR 2.9 MILLION YEAR AGO.  Full Article

Innate Pharma and Orega Biotech present preclinical data on IPH52
Tuesday, 19 Apr 2016 

Innate Pharma SA:Innate Pharma and Orega Biotech presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program.Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models.  Full Article

Innate Pharma presents new preclinical data supporting development of IPH4301
Monday, 18 Apr 2016 

Innate Pharma SA:New preclinical data further supporting development of IPH4301 presented at AACR meeting.Presented a new set of preclinical data further validating potential of its first-in-class anti-mica/b antibody IPH4301.  Full Article

Innate Pharma says DSMB meeting recommends continuation of EffiKIR trial
Wednesday, 16 Mar 2016 

Innate Pharma SA:Sixth DSMB meeting of the EffiKIR trial recommends continuation without modification.Data on primary endpoint, leukemia-free survival, are expected in second half of 2016.  Full Article

Innate Pharma to start phase I clinical trial of monalizumab
Monday, 8 Feb 2016 

Innate Pharma SA:Announces the start of phase I clinical trial of monalizumab in combination with durvalumab.‍This fifth trial with monalizumab completes roll-out of initial clinical plan, due to start reading out in 2017​.Trial ‍will include up to 208 patients, and will be performed in United States and in Europe.  Full Article

Innate Pharma enters licensing agreement with OREGA Biotech
Sunday, 10 Jan 2016 

Innate Pharma SA:Enters into an exclusive licensing agreement by which OREGA Biotech grants it full worldwide rights to its program of anti-CD39 checkpoint inhibitors.OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales.  Full Article

French and Benelux stocks-Factors to watch on Nov 23

Nov 23 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.